IS8461A - 2-(3,4-dímetýlfenýl)-4-{[2-hýdroxý-3'(1H-tetrasól-5-ýl)bífenýl-3-ýl]-hýdrasónó}-5-metýl-2,4-díhýdrópýrasól-3-ónkólín - Google Patents

2-(3,4-dímetýlfenýl)-4-{[2-hýdroxý-3'(1H-tetrasól-5-ýl)bífenýl-3-ýl]-hýdrasónó}-5-metýl-2,4-díhýdrópýrasól-3-ónkólín

Info

Publication number: IS8461A
Authority: IS; Iceland
Prior art keywords: ónkólín; dihydropyrazol; hydrazono; tetrazol; dimethylphenyl
Prior art date: 2003-10-22

Application number

IS8461A

Other languages

English (en)

Inventor

S. Brook Christopher

J. Ping Li-Jen

Original Assignee

Smithkline Beecham Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-22

Filing date

2006-05-12

Publication date

2006-05-12

2006-05-12 Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation

2006-05-12 Publication of IS8461A publication Critical patent/IS8461A/is

Links

-1 3,4-dimethylphenyl Chemical group 0.000 title 2
125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 title 1
125000005638 hydrazono group Chemical group 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Hematology (AREA)
Virology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)

IS8461A 2003-10-22 2006-05-12 2-(3,4-dímetýlfenýl)-4-{[2-hýdroxý-3'(1H-tetrasól-5-ýl)bífenýl-3-ýl]-hýdrasónó}-5-metýl-2,4-díhýdrópýrasól-3-ónkólín IS8461A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51348103P	2003-10-22	2003-10-22
PCT/US2004/034944 WO2005041867A2 (en)	2003-10-22	2004-10-21	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3’(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline

Publications (1)

Publication Number	Publication Date
IS8461A true IS8461A (is)	2006-05-12

Family

ID=34549283

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8461A IS8461A (is)	2003-10-22	2006-05-12	2-(3,4-dímetýlfenýl)-4-{[2-hýdroxý-3'(1H-tetrasól-5-ýl)bífenýl-3-ýl]-hýdrasónó}-5-metýl-2,4-díhýdrópýrasól-3-ónkólín

Country Status (19)

Country	Link
US (1)	US7666857B2 (is)
EP (1)	EP1684748A4 (is)
JP (1)	JP2007509159A (is)
KR (1)	KR20060095761A (is)
CN (1)	CN1897937B (is)
AR (1)	AR046188A1 (is)
AU (1)	AU2004285462B2 (is)
BR (1)	BRPI0415704A (is)
CA (1)	CA2543216A1 (is)
IL (1)	IL174924A0 (is)
IS (1)	IS8461A (is)
MA (1)	MA28113A1 (is)
MX (1)	MXPA06004483A (is)
NO (1)	NO20062111L (is)
NZ (1)	NZ546463A (is)
RU (1)	RU2379297C2 (is)
TW (1)	TW200526638A (is)
WO (1)	WO2005041867A2 (is)
ZA (1)	ZA200602901B (is)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CY2010012I2 (el)	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
TWI280128B (en)	2002-05-22	2007-05-01	Smithkline Beecham Corp	3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
US20070105824A1 (en) *	2003-04-29	2007-05-10	Erickson-Miller Connie L	Methods for treating degenerative diseases/injuries
US20100004302A1 (en) *	2003-04-29	2010-01-07	Connie Erickson-Miller	Methods for Treating Degenerative Diseases/Injuries
US20090143453A1 (en) *	2003-04-29	2009-06-04	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US20090048318A1 (en) *	2003-04-29	2009-02-19	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
TW200526638A (en)	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2007019522A2 (en) *	2005-08-04	2007-02-15	Carlos Lopez	Reversal of adult onset disorders with granulocyte-colony stimulating factors
WO2007044982A2 (en) *	2005-10-13	2007-04-19	Smithkline Beecham Corporation	Methods for the preservation of platelet efficacy during storage
US7879318B2 (en)	2006-01-23	2011-02-01	Mcw Research Foundation, Inc.	Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
GB0603522D0 (en) *	2006-02-22	2006-04-05	Avidex Ltd	Kinase inhibition
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
DK3127427T3 (da)	2009-05-29	2020-04-06	Novartis Ag	Fremgangsmåder til administration af trombopoietinagonistforbindelser
RU2469763C1 (ru) *	2011-11-16	2012-12-20	Анатолий Степанович Дресвянкин	Коньколыжи
JP2018521121A (ja)	2015-06-12	2018-08-02	アドハエアファーマシューティカルズ，インコーポレイティド	（ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE193350C (is)
US851444A (en) *	1905-11-13	1907-04-23	Agfa Ag	Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en)	1953-02-27	1957-07-24	Ciba Ltd	Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
GB826207A (en)	1956-07-23	1959-12-31	Bayer Ag	ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) *	1956-11-20	1960-08-23	Agfa Ag	Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) *	1965-04-09	1968-01-30	Interchem Corp	Disazo pyrazolone pigments
US4435417A (en) *	1981-02-20	1984-03-06	Gruppo Lepetit S.P.A.	Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES8503669A1 (es) *	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FI91869C (fi) *	1987-03-18	1994-08-25	Tanabe Seiyaku Co	Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) *	1987-10-30	1989-11-14	Baylor College Of Medicine	Method for preventing and treating thrombosis
US5326776A (en) *	1992-03-02	1994-07-05	Abbott Laboratories	Angiotensin II receptor antagonists
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de)	1993-08-13	1995-02-15	Ciba-Geigy Ag	Pigmentsalze
EP0661170B1 (en) *	1993-12-28	1998-09-02	Dai Nippon Printing Co., Ltd.	Thermal transfer sheet
US5482546A (en) *	1994-03-30	1996-01-09	Canon Kabushiki Kaisha	Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) *	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) *	1995-02-13	1998-05-05	Engelhard Corporation	Pigment compositions
BR9608587A (pt)	1995-06-07	1999-01-05	Glaxo Group Ltd	Composto que se liga ao receptor de trombopoietina composição farmacêutica e processo para o tratamento de um paciente sofrendo de um distúrbio
US5622818A (en) *	1995-11-29	1997-04-22	Eastman Kodak Company	Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) *	1996-05-30	1997-09-23	Engelhard Corporation	Pigment compositions
US5932546A (en) *	1996-10-04	1999-08-03	Glaxo Wellcome Inc.	Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
GB9715830D0 (en) *	1997-07-25	1997-10-01	Basf Ag	Reactive dyes containing piperazine
WO1999011262A1 (en)	1997-09-02	1999-03-11	Roche Diagnostics Gmbh	Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
WO1999022733A1 (en) *	1997-10-31	1999-05-14	Smithkline Beecham Corporation	Novel metal complexes
DE19851389A1 (de) *	1998-11-07	2000-05-11	Dystar Textilfarben Gmbh & Co	Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en)	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
CN1376150A (zh)	1999-07-26	2002-10-23	盐野义制药株式会社	具有血栓形成素受体拮抗作用的药物组合物
ATE315934T1 (de)	1999-09-10	2006-02-15	Smithkline Beecham Corp	Thrombopoietin-mimetika
WO2001021180A1 (en)	1999-09-24	2001-03-29	Smithkline Beecham Corporation	Thrombopoietin mimetics
AU1462201A (en)	1999-11-05	2001-06-06	Smithkline Beecham Corporation	Semicarbazone derivatives and their use as thrombopoietin mimetics
EP1104674A1 (de) *	1999-11-10	2001-06-06	Curacyte AG	O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
TWI284639B (en)	2000-01-24	2007-08-01	Shionogi & Co	A compound having thrombopoietin receptor agonistic effect
US6436915B1 (en) *	2000-04-07	2002-08-20	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
US6214813B1 (en) *	2000-04-07	2001-04-10	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
CY2010012I2 (el) *	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
CA2436288A1 (en)	2000-12-19	2002-06-27	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1351979B1 (en)	2000-12-21	2008-01-16	Smithkline Beecham Corporation	Regulated activation of cell-membrane receptors by metal-chelating agonists
WO2002059099A1 (fr)	2001-01-26	2002-08-01	Shionogi & Co., Ltd.	Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
EP1354880A4 (en) *	2001-01-26	2004-08-25	Shionogi & Co	HALOGEN COMPOUNDS HAVING AGONISM TOWARDS THROMBOPOIETIN RECEPTOR
WO2002085343A1 (en)	2001-03-01	2002-10-31	Smithkline Beecham Corporation	Thrombopoietin mimetics
US7105824B2 (en) *	2002-05-09	2006-09-12	Neurologica, Corp.	High resolution photon emission computed tomographic imaging tool
JP3927001B2 (ja)	2001-06-15	2007-06-06	三菱化学株式会社	色素セット、インクセット並びに記録方法
AU2002333114B2 (en)	2001-11-30	2008-09-04	Qlt Inc.	Hydrazonopyrazole derivatives and their use as therapeutics
WO2003074550A2 (en)	2002-03-01	2003-09-12	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
TWI280128B (en)	2002-05-22	2007-05-01	Smithkline Beecham Corp	3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4562523B2 (ja)	2002-06-06	2010-10-13	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	トロンボポエチン疑似体
US20060084682A1 (en)	2002-12-13	2006-04-20	Heerding Dirk A	Thrombopoietin mimetics
US20070105824A1 (en)	2003-04-29	2007-05-10	Erickson-Miller Connie L	Methods for treating degenerative diseases/injuries
TW200526638A (en)	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline

2004
- 2004-10-20 TW TW093131732A patent/TW200526638A/zh unknown
- 2004-10-21 KR KR1020067007688A patent/KR20060095761A/ko not_active Application Discontinuation
- 2004-10-21 BR BRPI0415704-4A patent/BRPI0415704A/pt not_active IP Right Cessation
- 2004-10-21 EP EP04796011A patent/EP1684748A4/en not_active Withdrawn
- 2004-10-21 NZ NZ546463A patent/NZ546463A/en unknown
- 2004-10-21 AR ARP040103827A patent/AR046188A1/es not_active Application Discontinuation
- 2004-10-21 RU RU2006117313/04A patent/RU2379297C2/ru not_active IP Right Cessation
- 2004-10-21 CA CA002543216A patent/CA2543216A1/en not_active Abandoned
- 2004-10-21 AU AU2004285462A patent/AU2004285462B2/en not_active Ceased
- 2004-10-21 JP JP2006536801A patent/JP2007509159A/ja active Pending
- 2004-10-21 US US10/576,411 patent/US7666857B2/en not_active Expired - Fee Related
- 2004-10-21 CN CN2004800384881A patent/CN1897937B/zh not_active Expired - Fee Related
- 2004-10-21 MX MXPA06004483A patent/MXPA06004483A/es active IP Right Grant
- 2004-10-21 WO PCT/US2004/034944 patent/WO2005041867A2/en active Application Filing
2006
- 2006-04-10 ZA ZA200602901A patent/ZA200602901B/en unknown
- 2006-04-11 IL IL174924A patent/IL174924A0/en unknown
- 2006-04-25 MA MA28969A patent/MA28113A1/fr unknown
- 2006-05-11 NO NO20062111A patent/NO20062111L/no not_active Application Discontinuation
- 2006-05-12 IS IS8461A patent/IS8461A/is unknown

Also Published As

Publication number	Publication date
WO2005041867A2 (en)	2005-05-12
MXPA06004483A (es)	2006-06-20
KR20060095761A (ko)	2006-09-01
AU2004285462A1 (en)	2005-05-12
CA2543216A1 (en)	2005-05-12
WO2005041867A8 (en)	2006-07-06
AR046188A1 (es)	2005-11-30
JP2007509159A (ja)	2007-04-12
CN1897937B (zh)	2010-11-24
BRPI0415704A (pt)	2006-12-19
NZ546463A (en)	2009-08-28
EP1684748A4 (en)	2009-12-09
RU2379297C2 (ru)	2010-01-20
US7666857B2 (en)	2010-02-23
WO2005041867A3 (en)	2005-10-13
CN1897937A (zh)	2007-01-17
US20070072922A1 (en)	2007-03-29
IL174924A0 (en)	2006-08-20
EP1684748A2 (en)	2006-08-02
NO20062111L (no)	2006-07-18
MA28113A1 (fr)	2006-08-01
ZA200602901B (en)	2008-02-27
TW200526638A (en)	2005-08-16
AU2004285462B2 (en)	2010-05-27
RU2006117313A (ru)	2007-11-27

Publication	Publication Date	Title
IS8461A (is)	2006-05-12	2-(3,4-dímetýlfenýl)-4-{[2-hýdroxý-3'(1H-tetrasól-5-ýl)bífenýl-3-ýl]-hýdrasónó}-5-metýl-2,4-díhýdrópýrasól-3-ónkólín
ATE452683T1 (de)	2010-01-15	3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3- methyl-5-oxo-4h-pyrazol-4-yliden hydrazino -2'- hydroxy- 1,1'-biphenyl -3-carbonsaure-bis- (monoethanolamin)
NO20041075L (no)	2004-03-15	Ny 1, 2, 4-triazolforbindelse
DK1492506T3 (da)	2009-03-16	Matrix for depot-, invariant- og uafhængig-frigörelse af aktive forbindelser
NO20011436D0 (no)	2001-03-21	2,2,6,6-dietyl-dimetyl-1-alkoksy-piperidin-forbindelser og deres korresponderende 1-oksider
AU2003266333A8 (en)	2004-03-19	4-(3,3-dihalo-allyloxy) phenol derivatives having pesticidal properties
ATE419254T1 (de)	2009-01-15	5-ää(2,3-difluorophenyl)methylüthioü-7-ää2- hydroxy-1-(hydroxymethyl)-1-
DE602004007387D1 (de)	2007-08-16	5-substituierte chinazolinonderivate
NO20020597L (no)	2002-04-03	1,4-substituerte 4,4-diaryl cykloheksaner
NL1022492A1 (nl)	2003-07-30	Slipmiddelen.
ITMI20031025A1 (it)	2004-11-22	Composizione d'inchiostro.
FR2863143B3 (fr)	2005-12-02	Releveur d'epis
NL1026862A1 (nl)	2005-02-22	Pyridoó3,4-d!pyrimidinederivaten als matrixmetalloproteïnase-13 remmers.
NO20044405L (no)	2004-10-15	Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
DE60318352D1 (de)	2008-02-14	Selbstnachstellender "winner-line-up" Verstärker
DK1529340T3 (da)	2006-06-12	Klasse D-forstærker
ATA19142002A (de)	2005-10-15	Sicherheitsdokument
DE60328736D1 (de)	2009-09-17	Thixogussverfahren
ES1054316Y (es)	2004-02-16	"forjado nervado"
NO20033536D0 (no)	2003-08-11	Snus-porsjonerer
ITPT20030007U1 (it)	2004-12-11	"mybox"
ES1054003Y (es)	2003-10-01	Pantalon perfeccionado.
ES1054247Y (es)	2003-10-16	Estuche para cd's
ITMC20020044A0 (it)	2002-05-23	"composizione polimerica per la bricchettatura".
ITRC20030003U1 (it)	2004-12-28	"portamonete"